Radium 223

Radium 223 is a radioactive treatment for men with metastatic prostate cancer in the bones.  This drug was developed in Norway by the company Algeta.   This revolutionary new treatment for recurrent prostate cancer improves cancer survival for men with advanced, metastatic prostate cancer.

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved. Disclaimer
Email: webmaster@urology.jhu.edu | 600 North Wolfe Street, Baltimore, Maryland 21287

urology second opinion urology second opinion